Growth hormone effect on body composition in Turner syndrome

Growth hormone effect on body composition in Turner syndrome

Author Baldin, Alexandre Duarte Google Scholar
Fabbri, Tatiana Autor UNIFESP Google Scholar
Siviero-Miachon, Adriana Aparecida Autor UNIFESP Google Scholar
Spinola-Castro, Angela Maria Autor UNIFESP Google Scholar
Valente de Lemos-Marini, Sofia Helena Google Scholar
Matias Baptista, Maria Tereza Google Scholar
Rodrigues D'Souza-Li, Lilia Freire Google Scholar
Maciel-Guerra, Andrea Trevas Google Scholar
Guerra-Junior, Gil Google Scholar
Institution Universidade Estadual de Campinas (UNICAMP)
Universidade Federal de São Paulo (UNIFESP)
Abstract This study analyzes the body composition of young adult women with Turner syndrome (TS) either treated or not treated with recombinant human growth hormone (rhGH) and compares them with a group of healthy women. Fifty-two non-treated TS patients (23.0 +/- A 5.8 years), 30 treated with rhGH (21.5 +/- A 1.5 years), and 133 healthy young adult women (22.9 +/- A 3.2 years) were evaluated regarding height (H) and weight, body mass index (BMI), brachial perimeter and tricipital cutaneous fold (fat and lean areas at the arm), sitting height (SRH = sitting height/H x 100), leg length (leg/H), waist and hip circumferences (waist/hip), and bioimpedance (percentages of water, lean mass, and fat mass). Age at start of rhGH therapy varied from 7.8 to 15.1 years (10.0 +/- A 1.3 years), duration of treatment from 2.8 to 8.2 years (3.7 +/- A 1.5 years), and the mean dose was 0.42 mg/kg/w (from 0.32 to 0.50 mg/kg/w). Body composition (except height) did not differ between TS groups, but there were differences when compared to the control group: weight and sitting height were lower in TS patients; and BMI, SHR, and leg/H were higher. There was an association between all groups with regards to BMI, waist, SHR, and leg/H, but not in percentage of fat mass. SHR was positively correlated with BMI, waist, hip, and percentage of fat mass. This sample of TS patients (with and without rhGH therapy) did not differ in BMI or body composition. However, there were differences between patients with TS patients and normal healthy women. Regardless of rhGH therapy, TS patients should be monitored, particularly for sitting height, SHR, leg length, leg/H, and waist/hip.
Keywords Hypogonadism
Body weight
Human adipose tissue
Obesity
Waist circumference
Growth hormone
Language English
Sponsor Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Date 2011-12-01
Published in Endocrine. Totowa: Humana Press Inc, v. 40, n. 3, p. 486-491, 2011.
ISSN 1355-008X (Sherpa/Romeo, impact factor)
Publisher Humana Press Inc
Extent 486-491
Origin http://dx.doi.org/10.1007/s12020-011-9504-z
Access rights Closed access
Type Article
Web of Science ID WOS:000296788000021
URI http://repositorio.unifesp.br/handle/11600/34283

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account